DYX-116

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameDYX-116
Drug Alias NameDYX116DYX-116
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucose-Dependent Insulinotropic Polypeptide Receptor agonistsGlucagon-like peptide 1 receptor agonistsGlucagon receptor agonists
TargetsGlucose-Dependent Insulinotropic Polypeptide ReceptorGlucagon-like peptide 1 receptorGlucagon receptor
Therapy Area/IndicationsOverweightObesityDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesJiangsu Deyuan Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesJiangsu Deyuan Pharmaceutical Co LtdWuxi Apptec(Shanghai) Co LtdShenzhen Jianxiang Biological Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsOverweightObesityDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A